Archive · 13 Aug 2025
Pancreatic Cancer Vaccine Shows Promise in Early Trial
Scientists are testing a new vaccine that may stop pancreatic cancer from coming back.
This vaccine works by targeting a specific gene mutation, KRAS, which is often found in this type of cancer.
In a small trial, the vaccine helped the body's immune system recognize and attack cancer cells.
Most patients showed a positive immune response.
The vaccine is designed to be a "one-size-fits-all", and results suggest it may extend the time people live after their cancer treatment, as people with pancreatic cancer don't usually live very long.
The vaccine could offer new hope, as the research continues.
A vaccine has shown promise in preventing the recurrence of pancreatic cancer in an early trial.
The vaccine targets KRAS gene mutations, common in many cancers.
Nearly 70% of patients in the Phase 1 trial developed a strong immune response.
Patients in the trial survived for approximately two years and five months after the vaccine.
The vaccine does not require personalization and can be mass-produced.
- Who
- Patients with pancreatic cancer participated in the trial.
- What
- A vaccine for pancreatic cancer showed promising results in a trial.
- When
- The trial was in early stages.
- Where
- The trial was conducted at an unspecified location.
- Why
- To prevent the recurrence of pancreatic cancer.
- Cancer Type
- Pancreatic
- Trial Phase
- Phase 1
- KRAS Mutations
- Target of the vaccine
- Survival Rate (Pancreatic Cancer)
- Around 13% at 5 years
- Immune Response
- Strong in nearly 70% of patients
- Survival time after vaccine
- Around 2 years and 5 months